Name

Leadart Biotechnologies

Legal name

LeadArt Biotechnologies, Inc.

Website

https://leadartech.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Drug Discovery Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

akta.pro secondary industries

High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Proteomics & Mass Spectrometry Services (HLAGANAB)

Keywords

• Chemoproteomics drug discovery
• Automated drug screening
• Target identification services
• Biotechnology automation equipment
• Live cell protein profiling

Headquarters

HQ city

Ningbo

HQ country

China

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Database Subscription and Licensing: Chem(Pro)2 database accessible via subscription, licensing, or customized solutions. Combines with automated Target Space Station to build proprietary, dynamic drug-target interaction databases at live-cell level.
2. Automated Chemoproteomics Services: Full automation from cell culture, drug incubation, protein extraction, peptide purification to proteomic samples. Each set of equipment can prepare over 20,000 samples annually. Professional services for research institutions and pharmaceutical companies.
3. Target Identification and Binding Site Services: PAL-AfBPP and ABPP-based services to identify targets and binding sites of active compounds in live cells. Provides mechanistic insights, off-target identification, and targets for new indications.
4. INTRAP® High-Throughput Drug Screening: Live-cell-based high throughput drug screening service using photoaffinity probes for ligand competition. Enables screening against almost any target without requiring protein isolation and purification.
5. Automation Equipment Sales: Sale of automated sample preparation equipment including Target Space Station, Cube, Eve, and Hive systems for chemoproteomics sample preparation.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

LeadArt Biotechnologies operates an integrated chemoproteomics, automation, and AI drug discovery platform that helps pharmaceutical companies and research institutions identify drug targets and screen compounds in live cells. Its core offerings include the INTRAP® live-cell target response analysis platform, a proprietary library of 4,000+ photoreactive and 300+ covalent probes, the Target Space Station automated sample preparation system, the Chem(Pro)2 protein-probe database, and Eve/Cube/Hive automation equipment. Revenue is generated through chemoproteomics service contracts, target identification studies, high-throughput drug screening services, database subscriptions and licensing, and equipment sales.

Product overview

LeadArt Biotechnologies offers a unified chemoproteomics-driven drug discovery platform combining four core technology areas: (1) INTRAP® - an AI-powered in-vivo target response analysis platform for live-cell drug screening; (2) Proprietary Probe Library - over 4,000 photoreactive probes and 300+ ABPP probes labeling 12,000+ human proteins; (3) Target Space Station - the first automated chemoproteomics sample preparation system with cell culture, probe/drug treatment, and proteome extraction modules; and (4) Chem(Pro)2 - the world's largest live-cell-level database of protein-probe interactions. These are supported by three automation equipment products (Eve Automated Cell Workstation, Cube Automated Incubator, Hive Sample Management System) that enable full-process automation of cell culture and compound management.

Differentiator

Problem solved

Functional benefit

Products and services

• INTRAP® (In-Vivo Target Response Analysis Platform) An in-vivo binding assay platform that measures ligand-target protein interactions via specifically designed probes, suitable for high-throughput screening of chemical ligands in food, dietary supplements, or pharmaceuticals for various protein targets without requiring protein modification or purification. Targets pharmaceutical and biotechnology R&D teams studying complex membrane proteins such as VEGFR and GPCRs.
• Target Space Station
• Chem(Pro)2 Database World's largest live-cell-level database integrating small-molecule probes/ligands with human proteins, supporting subscription, licensing, and customized solutions for drug repurposing, toxicity evaluation, and precision medicine. Targets pharmaceutical and biotechnology research teams seeking structured protein-probe interaction data.
• Proprietary Probe Library Library of over 4,000 photoaffinity active probes and 300+ ABPP (Activity-Based Protein Profiling) probes based on active scaffolds of approved drugs or drug-like molecules, capable of labeling over 12,000 human protein targets. Covers cancer, inflammation, cardiovascular, neurological, and metabolic diseases. Targets drug discovery researchers requiring chemical probes for previously under-studied proteins.
• Eve Automated Cell Workstation Fully automates cell handling and processing up to 150 T75 flasks per day, eliminating manual labor for cell culture operations. Targets biotechnology and pharmaceutical laboratories requiring high-throughput automated cell culture.
• Cube Automated Incubator Versatile automated cell culture incubator with integrated microscopy for real-time cell monitoring, supporting diverse automated cell culture workflows. Targets biotechnology and pharmaceutical laboratories requiring automated, observable cell culture.
• Hive Sample Management System Scalable automated sample management system capable of managing up to 5,000 samples per unit, expandable through networked integration. Targets biotechnology and pharmaceutical laboratories requiring high-volume sample tracking.

Quantifiable outcome

• Automated sample preparation achieves over 20,000 samples annually per equipment set, equivalent to output of 100 technicians
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature8 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Zhejiang UniversitycoreTechnology or Integration · 23 September 2025Jointly developed the iTarget AI model with Zhejiang University team as part of the integrated 'wet-dry experiment closed-loop' automated drug screening platform combining INTRAP® technology with AI analytics.
• YDS (Data Partner Program)minorGTM or Marketing Partner · 22 December 2023LeadArt joined YDS Data Partner Program to expand data ecosystem and collaboration opportunities.
• AstraZeneca iCampus (Chengdu International Life Science Innovation Park)coreStrategic or Co-development Partner · 5 November 2023LeadArt signed agreement to settle in Chengdu iCampus at CIIE 2023 to promote modernization of integration of Chinese and Western medicine. Partnership focuses on building a preclinical translation platform for traditional Chinese medicine in western China, linking ecosystem resources and building a modern innovation ecosystem.
• Hangzhou Keyone BiomedicalcoreTechnology or Integration · 1 June 2023Acquired Keyone Biomedical in 2021 to gain advanced capabilities in design and manufacturing of biotechnology automation equipment, establishing the automation team.

Scale indicators11 records

Recent moves13 records

Expansion highlights6 records

Direct peers

• Active Motif: Active Motif provides chemoproteomics and target identification services, including protein-probe interaction assays, and offers antibody/reagent products for epigenetics and gene regulation. Directly comparable to LeadArt's chemoproteomics target ID and probe library business.
• Reaction Biology: Reaction Biology offers a broad portfolio of drug discovery services including biochemical and cell-based assays, with strong chemoproteomics and activity-based protein profiling capabilities. Highly comparable to LeadArt's PAL-AfBPP/ABPP-based services and high-throughput screening offering.
• Carna Biosciences: Carna Biosciences specializes in kinase-focused chemoproteomics, covalent probe development, and target engagement assays, with a particular strength in profiling kinase inhibitors in live cells. Closely comparable to LeadArt's covalent probe library and live-cell drug screening approach.

Broad incumbents

• Eurofins Discovery: Eurofins Discovery is a large CRO offering integrated drug discovery services including compound profiling, in vitro pharmacology, and chemoproteomics. A broader incumbent whose portfolio overlaps with LeadArt's target ID, binding site mapping, and screening service lines.
• WuXi AppTec: WuXi AppTec is a China-rooted global CRO/CDMO offering end-to-end drug discovery, preclinical, and manufacturing services. Comparable to LeadArt as a Chinese-headquartered CRO serving global pharma with chemoproteomics-adjacent discovery capabilities.
• Charles River Laboratories: Charles River Labs is a global CRO providing drug discovery and safety assessment services with capabilities across cell biology, target validation, and high-content screening. Broadly comparable to LeadArt's discovery services and automation-led workflow positioning.
• Promega: Promega supplies life science reagents, assays, and integrated systems for protein interaction analysis, target engagement, and drug discovery. Adjacent competitor in target ID/binding site assays, with broader reagent portfolio scale.

Others

• Hamilton Company: Hamilton is a leading supplier of automated liquid handling workstations and laboratory automation for compound management, cell culture, and sample preparation. Directly comparable to LeadArt's Eve, Cube, and Hive automation equipment lines as competing lab automation platform.
• Tecan: Tecan is a major lab automation and detection instruments company offering automated sample preparation, cell handling, and integrated screening platforms. Overlaps with LeadArt's Target Space Station and cell-handling automation product line.
• Sartorius: Sartorius supplies bioprocessing, lab essentials, and cell culture automation equipment, including automated cell handling and incubation systems. Comparable to LeadArt's Eve Automated Cell Workstation and Cube Automated Incubator as a competing cell culture automation vendor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Leadart Biotechnologies